Erbitux Related Clinical Trials
Phase 1 and 2 Study of PX-866 and Cetuximab [Completed]
An Observational Study of Erbitux� in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment [Terminated]
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) [Completed]
Regorafenib and Cetuximab in Patients With Advanced Malignancy [Recruiting]
Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab [Recruiting]
Pre-op Rectal ChemoRad +/- Cetuximab [Active, not recruiting]
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib [Withdrawn]
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma [Recruiting]
Erlotinib in Combination With Cetuximab [Completed]
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer [Terminated]
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) [Not yet recruiting]
EMMA-1 (Erbitux for Multiple Myeloma) [Terminated]
Reirradiation and Erbitux in the HNSCC [Recruiting]
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer [Not yet recruiting]
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) [Withdrawn]
Sirolimus and Cetuximab in Advanced Malignancies [Completed]
Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer [Terminated]
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer [Completed]
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) [Completed]
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment [Completed]
Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck [Completed]
Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers [Recruiting]
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer [Active, not recruiting]
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) [Completed]
Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer [Completed]
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer [Recruiting]
Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® [Completed]
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer [Recruiting]
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer [Completed]
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination [Recruiting]
Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy [Recruiting]
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck [Terminated]
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer [Completed]
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver [Withdrawn]
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer [Completed]
Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer [Recruiting]
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer [Completed]
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery [Active, not recruiting]
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer [Recruiting]
Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer [Completed]
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer [Recruiting]
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma [Recruiting]
Cetuximab for Elderly Patients With mCRC [Active, not recruiting]
Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma [Completed]
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer [Terminated]
Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer [Completed]
Mitoxantrone � Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) [Active, not recruiting]
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) [Recruiting]
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma [Recruiting]
Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) [Recruiting]
Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer [Recruiting]
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA [Recruiting]
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors [Recruiting]
Cetuximab in Treating Patients With Advanced Solid Tumors [Completed]
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Thereapy for the Treatment of Unrespectable Recurrent Squamous Cell Carcinoma of the Head and Neck [Recruiting]
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) [Not yet recruiting]
Preoperative Treatment With Cetuximab and/or IMC-A12 [Active, not recruiting]
Erbitux MEtastatic Colorectal Cancer Strategy Study [Recruiting]
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer [Completed]
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer [Completed]
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer [Completed]
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients [Active, not recruiting]
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer [Completed]
Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy [Completed]
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC [Completed]
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab [Completed]
Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer [Terminated]
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC [Completed]
Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Completed]
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Recruiting]
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer [Completed]
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer [Terminated]
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer [Active, not recruiting]
Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC [Terminated]
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects [Completed]
Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma [Withdrawn]
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab [Completed]
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design [Recruiting]
Study of Sorafenib/Cetuximab in Head and Neck Cancer [Completed]
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces [Completed]
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer [Completed]
Lapatinib and Cetuximab in Patients With Solid Tumors [Completed]
Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab [Active, not recruiting]
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck [Withdrawn]
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer [Active, not recruiting]
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients [Completed]
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Completed]
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer [Active, not recruiting]
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea [Completed]
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck [Recruiting]
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer [Completed]
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer [Active, not recruiting]
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer [Completed]
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer [Recruiting]
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer [Terminated]
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN [Recruiting]
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer [Active, not recruiting]
A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck [Terminated]
|